Vitamin K intake and stability of oral anticoagulant treatment

Thrombosis and Haemostasis

Volumn 93, Issue 5, 2005, Pages 799-800

  Oldenburg, Johannes ^a  

^a University of Ulm   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4 CARBOXYGLUTAMIC ACID; ANTICOAGULANT AGENT; ANTIVITAMIN K; COUMARIN DERIVATIVE; CYTOCHROME P450 2C9; DICOUMAROL; GLUTAMIC ACID; MENADIONE EPOXIDE; OSTEOCALCIN; OXIDOREDUCTASE; UNCLASSIFIED DRUG; VITAMIN K 2,3 EPOXIDE REDUCTASE COMPLEX SUBUNIT 1; VITAMIN K DEPENDENT CARBOXYLASE; VITAMIN K GROUP; WARFARIN;

ANTICOAGULATION; BLEEDING; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG METABOLISM; DRUG TARGETING; EDITORIAL; FOOD DRUG INTERACTION; GENETIC VARIABILITY; HUMAN; INTERNATIONAL NORMALIZED RATIO; PRIORITY JOURNAL; THROMBOEMBOLISM; VITAMIN INTAKE;

ADMINISTRATION, ORAL; ANTICOAGULANTS; COUMARINS; HEMORRHAGE; HUMANS; INTERNATIONAL NORMALIZED RATIO; KINETICS; VITAMIN K;

EID: 18844385256     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH05-03-0190     Document Type: Editorial

References (15)

1. Campbell E, Link KP. Studies on the haemorrhagic sweet clover disease. J Biol Chem 1941; 138: 21-33.
2. Butt HR, Allen AV, Bollman JR. A preparation from spoiled sweet clover which prolongs coagulation toime and prothrombin time of blood. Proc Staff Meet Mayo Clin 1941; 16: 388-95.
3. Berkner KL, Runge KW. The physiology of vitamin K nutriture and vitamin K-dependent protein function in atherosclerosis. J Thromb Haemost 2004; 2: 2118-32.
4. Furie B, Bouchard BA, Furie BC. Vitamin K-dependent biosynthesis of γ-carboxyglutamic acid. Blood 1999; 93: 1798-808.
5. Rost S, Fregin A, Ivaskevicius V, et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 2004; 427: 537-41.
6. Li T, Chang CY, Jin DY, et al. Identification of the gene for vitamin K epoxide reductase. Nature 2004; 427: 541-4.
7. Booth SL, O'Brien-Morse ME, Dallal GE, et al. Response of vitamin K status to different intakes and sources of phylloquinone-rich foods: comparison of younger and older adults. Am J Clin Nutr 1999; 70: 369-77.
8. Margaglione M, Colaizzo D, D'Andrea G, et al. Genetic modulation of oral anticoagulation with warfarin. Thromb Haemost 2000; 84: 775-8.
9. D'Andrea G, D'Ambrosio RL, Di Perna P, et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 2005; 105: 645-9.
10. Palareti G, Leali N, Coccheri S et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 1996; 348: 423-8.
11. Sconce E, Khan T, Mason J, et al. Patients with unstable control have a poorer dietary intake of vitamin K compared to patients with stable control of anticoagulation. Thromb Haemost 2005; 93: 872-5.
12. Schurgers LJ, Shearer MJ, Halmujak K, et al. Effect of vitamin K intake on the stability of oral anticoagulant treatment: dose-response relationships in healthy subjects. Blood 2004; 104: 2682-9.
13. Hallgren KW, Hommema EL, McNally BA, et al. Carboxylase overexpression effects full carboxylation but poor release and secretion of factor IX: implications for the release of vitamin K-dependent proteins. Biochemistry 2002; 41: 15045-55.
14. Wajih N, Sane DC, Hutson SM, et al. Engineering of a recombinant vitamin K-dependent γ-carboxylation system with enhanced γ-carboxyglutamic acid forming capacity: Evidence for a functional CXXC RedOx center in the system. J Biol Chem 2005; 280: 10540-7.
15. Oldenburg J, Quenzel EM, Harbrecht U, et al. Missense mutation at Ala- 10 in the factor IX-propeptide: An insignificant variant in normal life but a decisive cause for bleeding during oral anticoagulant therapy. Br J Haematol 1997; 98: 240-4.